Home » Topics » BioWorld Science

BioWorld Science
RSS

CAR-iNKT cells safe and active in neuroblastoma patients

Oct. 7, 2019

GlaxoSmithKline initiates phase I study of GSK-2904545A vaccine candidate

Oct. 7, 2019

First-in-human study of apramycin

Oct. 7, 2019

Results presented from phase III SANET-ep study of surufatinib

Oct. 7, 2019

Symphogen presents early clinical data for Sym-015 in advanced solid tumors

Oct. 7, 2019

Development of novel sclerostin-resistant mouse model of T1D

Oct. 7, 2019

Shanghai Fochon Pharmaceutical, Fochon Pharmaceuticals patent TRK inhibitors

Oct. 7, 2019

Phase III data demonstrates equivalence between SB8 and bevacizumab in terms of best ORR

Oct. 7, 2019

Identification of PDE10A inhibitors with potential application in schizophrenia

Oct. 7, 2019

Deinove studies DNV-3837 in phase II for C. difficile infection

Oct. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...